FGFR2 Heme single gene test
Methodology
Molecular
Test Description and clinical significance
Genes
FGFR2
Disease:
Prostate cancer, cholangiocarcinoma, epidermal nevus, endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, cutaneous melanoma, colon adenocarcinoma, lung adenocarcinoma, gastric carcinoma, ovarian, cervical, pancreatic, head and neck cancers. Crouzon syndrome, Pfeiffer syndrome, Craniosynostosis, Apert syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrata syndrome, Saethre-Chotzen syndrome, and syndromic craniosynostosis.
Next generation sequencing of gene panel. The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.
Specimen Requirements
Collection:
3 mL of EDTA, citrate (ACD) or Heparinized bone marrow and peripheral blood specimens for RNA gene fusion detection
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
received within 96 hours of drawing. Samples that are 4 to 7 days old should be refrigerated.
CPT(s)
81479 or 81404
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
